NCT06195241View on ClinicalTrials.gov

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Benign Essential BlepharospasmHemifacial Spasm
Interventions
DRUG

DaxibotulinumtoxinA

Patients with Benign Essential Blepharospasm (BEB) or Hemifacial spasms (HFS) will be treated with DaxibotulinumtoxinA-Lanm (Daxxify) using a 2:1 conversion rate of Daxxify to Botox.

Trial Locations (1)

10466

RECRUITING

Montefiore Medical Center, The Bronx

All Listed Sponsors
collaborator

Revance Therapeutics, Inc.

INDUSTRY

lead

Montefiore Medical Center

OTHER

NCT06195241 - Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm | Biotech Hunter | Biotech Hunter